ADCendo is a technology company.
Adcendo ApS is a global clinical-stage biotech company dedicated to developing highly differentiated first and best-in-class antibody-drug conjugates (ADCs) for targeted treatment of cancer.
ADCendo has raised $253.0M across 4 funding rounds.
ADCendo has raised $253.0M in total across 4 funding rounds.
ADCendo has raised $253.0M in total across 4 funding rounds.
ADCendo's investors include Access Biotechnology, Andera Partners, HealthCap, Pontifax Venture Capital, RA Capital, Ysios Capital.
Adcendo is a clinical-stage biotech company developing first-in-class antibody-drug conjugates (ADCs) for targeted cancer treatment, focusing on solid tumors and hematologic malignancies with high unmet needs.[1][2][3][4] It builds therapies like ADCE-D01, which targets the uPARAP receptor overexpressed in mesenchymal cancers such as soft tissue sarcomas, serving oncology patients underserved by current options.[1][4] The company solves the problem of imprecise cancer therapies by delivering cytotoxic payloads directly to tumor cells via novel ADC designs, with strong growth shown through $248.76M raised (latest $135M Series B six months ago) and FDA Fast Track for ADCE-D01.[1][4]
Headquartered in Copenhagen, Denmark, Adcendo aims to lead Europe in ADCs, guided by patient-centric, science-driven values.[3][4] Its pipeline advances rapidly, with the first patient dosed in the Phase I/II ADCElerate1 trial for ADCE-D01 and active participation in investor events.[4]
Adcendo was founded in 2017 in Frederiksberg, Denmark, by experts including co-founder Niels Behrendt and Chief Scientific Officer Dominik Mumberg, leveraging deep knowledge in oncology and ADC technology.[1][4][5] The idea emerged from identifying novel targets overexpressed in hard-to-treat cancers, addressing gaps in existing treatments for solid tumors and blood cancers.[2][3]
Early traction built through targeted funding: an €82M Series A (including a €31M extension led by Pontifax Venture Capital with Novo Holdings and Ysios Capital), followed by a $135M Series B.[1][2] Pivotal moments include collaborations like with Duality Biologics and recent clinical milestones, such as dosing the first patient in ADCE-D01's trial and securing FDA Fast Track Designation in 2025.[1][4]
Adcendo stands out in the ADC field through:
Adcendo rides the ADC boom, a trend exploding due to successes like Enhertu, with market forces favoring precision oncology amid rising cancer incidence and demand for targeted therapies over chemotherapies.[1][2][4] Timing is ideal: post-2020 ADC approvals have validated the modality, while soft tissue sarcoma pipelines (70+ companies) highlight competition yet gaps Adcendo fills via unique uPARAP targeting.[1]
It influences the ecosystem by pioneering European ADC innovation, fostering collaborations (e.g., Duality Biologics), and advancing underserved indications like sarcomas, potentially accelerating global access to differentiated therapies.[2][4]
Adcendo's trajectory points to key catalysts ahead: ADCElerate1 data readouts, pipeline expansions, and potential partnerships/big pharma deals, fueled by its Series B war chest.[1][4] Trends like AI-optimized payloads and combo therapies will shape ADCs, positioning Adcendo to capture share in the $10B+ market if clinical results confirm efficacy in sarcomas and beyond.[1]
Its influence could evolve from clinical pioneer to commercial leader, transforming outcomes for hard-to-treat cancers—echoing its origins in unmet needs with precision therapies designed for life.[3][4]
ADCendo has raised $253.0M across 4 funding rounds. Most recently, it raised $140.0M Series B in November 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2024 | $140.0M Series B | Access Biotechnology, Andera Partners, HealthCap, Pontifax Venture Capital, RA Capital, Ysios Capital | |
| May 1, 2024 | $17.0M Series A | Access Biotechnology, HealthCap, Pontifax Venture Capital, RA Capital, Ysios Capital | |
| Apr 1, 2023 | $34.0M Series A | Access Biotechnology, Andera Partners, HealthCap, Pontifax Venture Capital, RA Capital, Ysios Capital | |
| Apr 1, 2021 | $62.0M Series A | Andera Partners, HealthCap, Pontifax Venture Capital, RA Capital, Ysios Capital |